---
category: news
title: "Exelixis licenses AI-designed cancer drug from Insilico Medicine"
excerpt: "Insilico Medicine is due to receive $80 million upfront plus potential milestone payments as Exelixis gains global rights to develop and commercialize the Hong Kong firmâ€™s small molecule cancer treatment."
publishedDateTime: 2023-09-14T14:24:00Z
originalUrl: "https://www.outsourcing-pharma.com/Article/2023/09/14/exelixis-licenses-ai-designed-cancer-drug-from-insilico-medicine"
webUrl: "https://www.outsourcing-pharma.com/Article/2023/09/14/exelixis-licenses-ai-designed-cancer-drug-from-insilico-medicine"
type: article
quality: 39
heat: 39
published: false

provider:
  name: Outsourcing-pharma
  domain: outsourcing-pharma.com

topics:
  - Facebook AI
  - AI

images:
  - url: "https://www.outsourcing-pharma.com/var/wrbm_gb_food_pharma/storage/images/publications/pharmaceutical-science/outsourcing-pharma.com/headlines/clinical-development/exelixis-licenses-ai-designed-cancer-drug-from-insilico-medicine/16747547-1-eng-GB/Exelixis-licenses-AI-designed-cancer-drug-from-Insilico-Medicine.jpg"
    width: 1500
    height: 1000
    isCached: true

secured: "rCqMJoZFbRDIQBSqIp5riq2lgHfVJthVFlGZixfsdHovZUE5UhneDIkPXtvIIE9ioI0SJF9A6u3JZckdo47/MMo/6Ftt4Z1Bl6QK7s7mUM0ct6J1I0aXPYJ1fEpTIssvvIW8ryimGilK3hqiTltY4zJvg4fqMNFItq8e940vnwahhdy+eX5XyVche1EAXTM8VHUk7WVfxwqaFuOnx0WBznlfB2gTIzQyidBP01D6OsQ3e8P2ckkn/vcMUqj3Q+Df0Bxf0w2v1tr8KXNqXOA43QiANuGENLoadWu/9WZXS3JAuilPrEwyg2apl24GuE1u6eReXtamskzEqEXTOV6ogaXRLa/zOEqfJRxu6M/ODIc=;LYzpuDvq0YLl6pgT221JgQ=="
---

